Genomic, pathological, and clinical heterogeneity as drivers of personalized medicine in prostate cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 33, Issue 2, 2015, Pages 85-94

  Fraser, Michael ^a   Berlin, Alejandro ^a,b   Bristow, Robert G ^a,b   Van der Kwast, Theodorus ^c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Genomics; Heterogeneity; Molecular oncology; Personalized cancer medicine; Prognosis; Prostate cancer; Radiotherapy; Surgery

Indexed keywords

RNA;

CANCER GENETICS; CANCER PROGNOSIS; CANCER RISK; CLINICAL FEATURE; CLONAL VARIATION; COPY NUMBER VARIATION; FUSION GENE; GENE EXPRESSION; GENE SEQUENCE; GENETIC HETEROGENEITY; GENETIC MARKER; GENETIC VARIABILITY; GENOMICS; HUMAN; MALE; OUTCOME ASSESSMENT; PERSONALIZED MEDICINE; POINT MUTATION; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SYSTEMIC DISEASE; GENETICS; PATHOLOGY; PROCEDURES; PROGNOSIS; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

GENOMICS; HUMANS; MALE; PRECISION MEDICINE; PROGNOSIS; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

EID: 84923623092     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2013.10.020     Document Type: Review

References (73)

1. Nichol A.M., Warde P., Bristow R.G. Optimal treatment of intermediate-risk prostate carcinoma with radiotherapy: clinical and translational issues. Cancer 2005, 104:891-905.
2. D'Amico A.V., Cote K., Loffredo M., Renshaw A.A., Chen M.H. Pretreatment predictors of time to cancer specific death after prostate specific antigen failure. J Urol 2003, 169:1320-1324.
3. D'Amico A.V., Moul J., Carroll P.R., Sun L., Lubeck D., Chen M.H. Cancer-specific mortality after surgery or radiation for patients with clinically localized prostate cancer managed during the prostate-specific antigen era. J Clin Oncol 2003, 21:2163-2172.
4. Morgan S.C., Waldron T.S., Eapen L., Mayhew L.A., Winquist E., Lukka H. Adjuvant radiotherapy following radical prostatectomy for pathologic T3 or margin-positive prostate cancer: a systematic review and meta-analysis. Radiother Oncol 2008, 88:1-9.
5. King C.R. The timing of salvage radiotherapy after radical prostatectomy: a systematic review. Int J Radiat Oncol Biol Phys 2012, 84:104-111.
6. Mukherji D., Eichholz A., De Bono J.S. Management of metastatic castration-resistant prostate cancer: recent advances. Drugs 2012, 72:1011-1028.
7. Yap T.A., Swanton C., de Bono JS. Personalization of prostate cancer prevention and therapy: are clinically qualified biomarkers in the horizon?. EPMA J 2012, 3:3.
8. Grimm P., Billiet I., Bostwick D., Dicker A.P., Frank S., Immerzeel J., et al. Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. Br J Urol Int 2012, 109(Suppl. 1):22-29.
9. Kollmeier M.A., Zelefsky M.J. How to select the optimal therapy for early-stage prostate cancer. Crit Rev Oncol Hematol 2012, 83:225-234.
10. Klotz L. Active surveillance for prostate cancer: overview and update. Curr Treat Options Oncol 2013, 14:97-108.
11. Villers A., McNeal J.E., Freiha F.S., Stamey T.A. Multiple cancers in the prostate. Morphologic features of clinically recognized versus incidental tumors. Cancer 1992, 70:2313-2318.
12. Wolters T., Montironi R., Mazzucchelli R., Scarpelli M., Roobol M.J., van den Bergh R.C., et al. Comparison of incidentally detected prostate cancer with screen-detected prostate cancer treated by prostatectomy. Prostate 2012, 72:108-115.
13. Taylor B.S., Schultz N., Hieronymus H., Gopalan A., Xiao Y., Carver B.S., et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010, 18:11-22.
14. Liu W., Laitinen S., Khan S., Vihinen M., Kowalski J., Yu G., et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 2009, 15:559-565.
15. Mehra R., Tomlins S.A., Yu J., Cao X., Wang L., Menon A., et al. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res 2008, 68:3584-3590.
16. Aryee M.J., Liu W., Engelmann J.C., Nuhn P., Gurel M., Haffner M.C., et al. DNA methylation alterations exhibit intraindividual stability and interindividual heterogeneity in prostate cancer metastases. Sci Transl Med 2013, 5:169ra10.
17. Cooper C.S., Foster C.S. Concepts of epigenetics in prostate cancer development. Br J Cancer 2009, 100:240-245.
18. Locke J.A., Zafarana G., Ishkanian A.S., Milosevic M., Thoms J., Have C.L., et al. NKX3.1 haploinsufficiency is prognostic for prostate cancer relapse following surgery or image-guided radiotherapy. Clin Cancer Res 2012, 18:308-316.
19. Attard G., Ang J.E., Olmos D., de Bono J.S. Dissecting prostate carcinogenesis through ETS gene rearrangement studies: implications for anticancer drug development. J Clin Pathol 2008, 61:891-896.
20. Yoshimoto M., Ding K., Sweet J.M., Ludkovski O., Trottier G., Song K.S., et al. PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade. Mod Pathol 2013, 26:435-447.
21. Minner S., Gartner M., Freudenthaler F., Bauer M., Kluth M., Salomon G., et al. Marked heterogeneity of ERG expression in large primary prostate cancers. Mod Pathol 2013, 26:106-116.
22. Gerlinger M., Rowan A.J., Horswell S., Larkin J., Endesfelder D., Gronroos E., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. New Engl J Med 2012, 366:883-892.
23. Joshua A.M., Vukovic B., Braude I., Hussein S., Zielenska M., Srigley J., et al. Telomere attrition in isolated high-grade prostatic intraepithelial neoplasia and surrounding stroma is predictive of prostate cancer. Neoplasia 2007, 9:81-89.
24. Lee S.E., Kim D.S., Lee W.K., Park H.Z., Lee C.J., Doo S.H., et al. Application of the Epstein criteria for prediction of clinically insignificant prostate cancer in Korean men. Br J Urol Int 2010, 105:1526-1530.
25. Miyagi Y., Sasaki T., Fujinami K., Sano J., Senga Y., Miura T., et al. ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples. Mod Pathol 2010, 23:1492-1498.
26. Mao X., Yu Y., Boyd L.K., Ren G., Lin D., Chaplin T., et al. Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis. Cancer Res 2010, 70:5207-5212.
27. Rosen P., Pfister D., Young D., Petrovics G., Chen Y., Cullen J., et al. Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American patients with prostate cancer. Urology 2012, 80:749-753.
28. Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70. The Cancer Genome Atlas.
29. Van der Kwast T.H., Roobol M.J. Defining the threshold for significant versus insignificant prostate cancer. Nat Rev Urol 2013, 10:473-482.
30. Ross H.M., Kryvenko O.N., Cowan J.E., Simko J.P., Wheeler T.M., Epstein J.I. Do adenocarcinomas of the prostate with Gleason score (GS)
31. Penney K.L., Sinnott J.A., Fall K., Pawitan Y., Hoshida Y., Kraft P., et al. mRNA expression signature of Gleason grade predicts lethal prostate cancer. J Clin Oncol 2011, 29:2391-2396.
32. Sowalsky A.G., Ye H., Bubley G.J., Balk S.P. Clonal progression of prostate cancers from Gleason grade 3 to grade 4. Cancer Res 2013, 73:1050-1055.
33. Baca S.C., Prandi D., Lawrence M.S., Mosquera J.M., Romanel A., Drier Y., et al. Punctuated evolution of prostate cancer genomes. Cell 2013, 153:666-677.
34. Kovtun, Cheville J.C., Murphy S.J., Johnson S.H., Zarei S., Kosari F., et al. Lineage relationship of Gleason patterns in Gleason score 7 prostate cancer. Cancer Res 2013, 73:3275-3284.
35. Paris P.L., Weinberg V., Albo G., Roy R., Burke C., Simko J., et al. A group of genome-based biomarkers that add to a Kattan nomogram for predicting progression in men with high-risk prostate cancer. Clin Cancer Res 2010, 16:195-202.
36. Schaefer A., Jung M., Mollenkopf H.J., Wagner I., Stephan C., Jentzmik F., et al. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 2010, 126:1166-1176.
37. Leite K.R., Tomiyama A., Reis S.T., Sousa-Canavez J.M., Sanudo A., Dall'Oglio M.F., et al. MicroRNA-100 expression is independently related to biochemical recurrence of prostate cancer. J Urol 2011, 185:1118-1122.
38. Spahn M., Kneitz S., Scholz C.J., Stenger N., Rudiger T., Strobel P., et al. Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int J Cancer 2010, 127:394-403.
39. Martens-Uzunova E.S., Jalava S.E., Dits N.F., van Leenders G.J., Moller S., Trapman J., et al. Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer. Oncogene 2012, 31:978-991.
40. Cuzick J., Swanson G.P., Fisher G., Brothman A.R., Berney D.M., Reid J.E., et al. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol 2011, 12:245-255.
41. Freedland S.J., Gerber L., Reid J., Welbourn W., Tikishvili E., Park J., et al. Prognostic utility of cell cycle progression score in men with prostate cancer after primary external beam radiation therapy. Int J Radiat Oncol Biol Phys 2013, 86:848-853.
42. Cuzick J., Berney D.M., Fisher G., Mesher D., Moller H., Reid J.E., et al. Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort. Br J Cancer 2012, 106:1095-1099.
43. Cooperberg M.R., Simko J.P., Cowan J.E., Reid J.E., Djalilvand A., Bhatnagar S., et al. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol 2013, 31:1428-1434.
44. Erho N., Crisan A., Vergara I.A., Mitra A.P., Ghadessi M., Buerki C., et al. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PloS One 2013, 8:e66855.
45. Karnes R.J., Bergstralh E.J., Davicioni E., Ghadessi M., Buerki C., Mitra A.P., et al. Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. J Urol 2013, 190:2047-2053.
46. Wu C.L., Schroeder B.E., Ma X.J., Cutie C.J., Wu S., Salunga R., et al. Development and validation of a 32-gene prognostic index for prostate cancer progression. Proc Natl Acad Sci U S A 2013, 110:6121-6126.
47. Ding Z., Wu C.J., Chu G.C., Xiao Y., Ho D., Zhang J., et al. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 2011, 470:269-273.
48. Weischenfeldt J., Simon R., Feurbach L., Schlangen K., Weichenhan D., Minner S., et al. Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer cell 2013, 23:159-170.
49. Robbins C.M., Tembe W.A., Baker A., Sinari S., Moses T.Y., Beckstrom-Sternberg S., et al. Copy number and targeted mutational analysis reveals novel somatic events in metastatic prostate tumors. Genome research 2011, 21:47-55.
50. Kumar A., White T.A., MacKenzie A.P., Clegg N., Lee C., Dumpit R.F., et al. Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:17087-17092.
51. Berger M.F., Lawrence M.S., Demichelis F., Drier Y., Cibulskis K., Sivachenko A.Y., et al. The genomic complexity of primary human prostate cancer. Nature 2011, 470:214-220.
52. Grasso C.S., Wu Y.M., Robinson D.R., Cao X., Dhanasekaran S.M., Khan A.P., et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012, 487:239-243.
53. Borno S.T., Fischer A., Kerick M., Falth M., Laible M., Brase J.C., et al. Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation. Cancer Discov 2012, 2:1024-1035.
54. Barbieri C.E., Baca S.C., Lawrence M.S., Demichelis F., Blattner M., Theurillat J.P., et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nature genetics 2012, 44:685-689.
55. Kron K., Liu L., Trudel D., Pethe V., Trachtenberg J., Fleshner N., et al. Correlation of ERG expression and DNA methylation biomarkers with adverse clinicopathologic features of prostate cancer. Clin Cancer Res 2012, 18:2896-2904.
56. Kron K., Trudel D., Pethe V., Briollais L., Fleshner N., van der Kwast T., et al. Altered DNA methylation landscapes of polycomb-repressed loci are associated with prostate cancer progression and ERG oncogene expression in prostate cancer. Clin Cancer Res 2013, 19:3450-3461.
57. Stephens P.J., Greenman C.D., Fu B., Yang F., Bignell G.R., Mudie L.J., et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development. Cell 2011, 144:27-40.
58. Beltran H., Rickman D.S., Park K., Chae S.S., Sboner A., MacDonald T.Y., et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov 2011, 1:487-495.
59. Wu C., Wyatt A.W., Lapuk A.V., McPherson A., McConeghy B.J., Bell R.H., et al. Integrated genome and transcriptome sequencing identifies a novel form of hybrid and aggressive prostate cancer. J Pathol 2012, 227:53-61.
60. Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G., et al. Patterns of somatic mutation in human cancer genomes. Nature 2007, 446:153-158.
61. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455:1061-1068. The Cancer Genome Atlas.
62. Ding L., Getz G., Wheeler D.A., Mardis E.R., McLellan M.D., Cibulskis K., et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455:1069-1075.
63. Wood L.D., Parsons D.W., Jones S., Lin J., Sjoblom T., Leary R.J., et al. The genomic landscapes of human breast and colorectal cancers. Science 2007, 318:1108-1113.
64. Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Angenendt P., et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321:1801-1806.
65. Parsons D.W., Jones S., Zhang X., Lin J.C., Leary R.J., Angenendt P., et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321:1807-1812.
66. Ley T.J., Mardis E.R., Ding L., Fulton B., McLellan M.D., Chen K., et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature 2008, 456:66-72.
67. Mardis E.R., Ding L., Dooling D.J., Larson D.E., McLellan M.D., Chen K., et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. New Engl J Med 2009, 361:1058-1066.
68. Shah S.P., Morin R.D., Khattra J., Prentice L., Pugh T., Burleigh A., et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009, 461:809-813.
69. Yan H., Parsons D.W., Jin G., McLendon R., Rasheed B.A., Yuan W., et al. IDH1 and IDH2 mutations in gliomas. New Engl J Med 2009, 360:765-773.
70. Ghiam A.F., Cairns R.A., Thoms J., Dal Pra A., Ahmed O., Meng A., et al. IDH mutation status in prostate cancer. Oncogene 2012, 31:3826.
71. Nickerson M.L., Im K.M., Misner K.J., Tan W., Lou H., Gold B., et al. Somatic alterations contributing to metastasis of a castration-resistant prostate cancer. Hum Mutat 2013, 34:1231-1241.
72. Roychowdhury S., Iyer M.K., Robinson D.R., Lonigro R.J., Wu Y.M., Cao X., et al. Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med 2011, 3:111ra21.
73. Haffner M.C., Mosbruger T., Esopi D.M., Fedor H., Heaphy C.M., Walker D.A., et al. Tracking the clonal origin of lethal prostate cancer. Journal of clinical investigation 2013, 123:4918-4922.